Biohaven Relaunches As Biohaven Ltd. After Pfizer Buyout Closes
As signaled when Pfizer acquired Biohaven’s Nurtec and CGRP assets, Biohaven will continue under a modified name, with a focus on epilepsy, obsessive compulsive disorder and spinal muscular atrophy.
You may also be interested in...
The company, which has struggled in the clinic following a deal where Pfizer bought its migraine portfolio, is licensing the dual inhibitor drug from a Chinese firm for up to $970m.
Pfizer plans to build on the momentum gained for its oral drug Nurtec ODT, now the leading CGRP inhibitor, with the intranasal Zavzpret, which will be priced in line with the rest of the class.
Many of the same factors that held down large M&A transactions in 2021 carried over to 2022, which saw eight buyouts valued at $2bn+, headlined by Amgen’s $27.8bn purchase of Horizon.